ERBB2 and gastric cancer: We performed immunohistochemical and immunofluorescent analysis of the gastric cancer TMAs to determine the clinical relevance of SHCBP1 and HER2, demonstrating a weak to moderate correlation between HER2 and SHCBP1 expression (Spearman coefficient = 0.36, Fig. 2e, f).